Document Detail

Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.
MedLine Citation:
PMID:  11011346     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, altered endothelial function in patients with coronary hypercholesterolemia and its modifications by treatment with enalapril and simvastatin, either separately or in combination, was assessed in the brachial artery in a randomized, double-blind, 2-period crossover study. METHODS: Thirty-eight patients were separated in 2 groups. Group 1 (18 patients, 3 female, mean age 63 +/- 6.0 years) received simvastatin 10 mg/d for 8 weeks and simvastatin plus enalapril 5 mg/d for another 8 weeks. Group 2 (20 patients, 3 female, mean age 64 +/- 5.8 years) received enalapril 5 mg/d for 8 weeks and enalapril plus simvastatin 10 mg/d for another 8 weeks. All subjects underwent measurements of brachial artery diameter before and after postischemic hyperemia with high-resolution ultrasound at basal conditions (control) and under the effects of the drugs at the end of 8 and 16 weeks. RESULTS: Cholesterol and LDL cholesterol levels significantly decreased with simvastatin treatment alone or with enalapril. Mean baseline arterial diameter was 5.24 +/- 1.25 mm in group 1 and 4.83 +/- 0.99 mm in group 2 (not significant). In group 1 after the first 8 weeks, endothelium-dependent vasodilation significantly increased with simvastatin treatment (control, 4.4%; 8 weeks, 7.6%; P <.001). After 16 weeks with the addition of enalapril, a further increase in vasodilation was seen (8.6%, P <.05 vs 8 weeks). In group 2, with enalapril treatment an increase in vasodilation versus control was seen (control, 4.3%; 8 weeks, 5.8%; P <.01). After 16 weeks, with the addition of simvastatin an additional increase in vasodilation was observed (9.1%, P <.001 vs 8 weeks). After nitroglycerin, vasodilation in group 1 at control, 8, and 16 weeks was 17%, 17.5%, and 18%, respectively. In group 2, nitroglycerin vasodilation at control, 8, and 16 weeks was 21%, 21%, and 22%, respectively. CONCLUSIONS: Simvastatin significantly increased the postischemic vasodilator response in patients with coronary hypercholesterolemia, either as single treatment or added to enalapril. Similarly, the response was increased by enalapril, either alone or while simvastatin was being administered. Both drugs improve vasodilation and additive effects appear to be present.
R J Esper; R Machado; J Vilariño; J L Cacharrón; C A Ingino; C A García Guiñazú; E Bereziuk; A L Bolaño; D H Suarez
Related Documents :
15910556 - Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvasta...
18614926 - Lipid and apoprotein profile in hiv-1-infected patients after cd4-guided treatment inte...
19614946 - Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabete...
14976546 - Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous ...
16803916 - Case series: monocular visual loss associated with subarachnoid hemorrhage secondary to...
19578176 - Acute and long-term outcome of cryoablation therapy of typical atrioventricular nodal r...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  140     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-10-18     Completed Date:  2000-11-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  684-9     Citation Subset:  AIM; IM    
Department of Medicine, University of Buenos Aires, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Brachial Artery / drug effects,  physiopathology,  ultrasonography
Cholesterol / blood
Coronary Disease / blood,  drug therapy*,  physiopathology
Cross-Over Studies
Double-Blind Method
Drug Therapy, Combination
Enalapril / therapeutic use*
Endothelium, Vascular / drug effects,  physiopathology*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / blood,  drug therapy*,  physiopathology
Middle Aged
Simvastatin / therapeutic use*
Vasodilation / drug effects
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol; 75847-73-3/Enalapril; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of test...
Next Document:  Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter.